{"product_id":"rsk2-antibody-sc-f0904","title":"Phospho-RSK2 (Ser227) Antibody","description":"\u003ch2\u003eAbout the Target\u003c\/h2\u003e\u003cp\u003ePhospho-RSK2 (Ser227) refers to the phosphorylated form of ribosomal S6 kinase 2 (RSK2) at serine residue 227. Ribosomal protein S6 kinase 2 (RSK2), also known as RPS6KA3, is a serine\/threonine kinase that acts as a downstream effector of the RAS\/RAF\/MEK\/ERK signaling pathway. Structurally, RSK2 contains two functional kinase domains: the N-terminal kinase domain (NTKD) and the C-terminal kinase domain (CTKD), linked by a regulatory linker domain. Depending on the literature source, RSK2 may also be discussed as Phospho-RSK2 (Ser227) and S6K-alpha-3.\u003c\/p\u003e\u003cp\u003eReported cellular context includes cytoplasm and nucleus, which can matter when signal is compared across treatments or changing cell states. Following RSK2 across matched perturbations can help separate abundance effects from shifts in localization, complex assembly, or pathway state.\u003c\/p\u003e\u003ch2\u003eResearch Context\u003c\/h2\u003e\u003cp\u003eRSK2 is commonly interpreted in the context of cancer and cell signaling research, and readouts are often stronger when a study separates expression changes from compartment-level redistribution. When reported signal spans cytoplasm and nucleus, a defined reference condition can make comparisons more interpretable across perturbations, passages, or replicate sets.\u003c\/p\u003e\u003cp\u003eConsider these angles when interpreting target-level changes:\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eapparent redistribution between cytoplasm and nucleus across matched conditions\u003c\/li\u003e\n\u003cli\u003echanges associated with proliferative state, oncogenic signaling, or treatment response\u003c\/li\u003e\n\u003cli\u003esignal-dependent shifts after ligand, inhibitor, or growth-factor perturbation\u003c\/li\u003e\n\u003cli\u003edifferences between total target abundance and site-specific regulation when modified forms are compared\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eVariant Considerations\u003c\/h2\u003e\u003cp\u003eIf your project spans exploratory questions, the regular version offers a balanced option for establishing baseline signal behavior for RSK2. This can help when protocols evolve over time and the goal is to compare experiments using a stable reference workflow.\u003c\/p\u003e\u003cp\u003eStandardize sampling time, control choice, and downstream analysis thresholds so apparent differences in RSK2 reflect biology rather than handling. When interpreting RSK2, it is often useful to decide early whether the main question is overall abundance, compartmental enrichment, or context-dependent redistribution.\u003c\/p\u003e\u003cp\u003eFor multi-run studies, a shared reference condition can keep RSK2 trends easier to compare across datasets. That kind of consistency is especially helpful when follow-up work expands to new perturbations, model systems, or longitudinal collections.\u003c\/p\u003e","brand":"Selleck Chemicals","offers":[{"title":"20 µl","offer_id":57577561719129,"sku":"F0904-20UL","price":169.0,"currency_code":"EUR","in_stock":true},{"title":"100 µl","offer_id":57577561751897,"sku":"F0904-100UL","price":389.0,"currency_code":"EUR","in_stock":true},{"title":"2 × 100 µl","offer_id":57577561784665,"sku":"F0904-2X100UL","price":579.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0923\/1011\/0553\/files\/F0904-wb.gif?v=1773599080","url":"https:\/\/absource-diagnostics.myshopify.com\/products\/rsk2-antibody-sc-f0904","provider":"Absource Diagnostics","version":"1.0","type":"link"}